2nd Quarter - Report

AMERICAN SOCIETY OF HEMATOLOGY for AMERICAN SOCIETY OF HEMATOLOGY

Firm
Client
Income
—
Expenses
$30,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721) One Big Beautiful Bill Act (H.R. 1) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: SENATE; Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (119th), S. 721 (119th), S. 1936 (119th)

Budget/Appropriations BUD

Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) FY 2026 NIH funding FY 2026 AHRQ funding FY 2026 CDC funding FY 2026 funding for CDC Sickle Cell Data Collection program FY 2026 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2026 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) Impact of restructuring and reorganization of federal public health and research agencies One Big Beautiful Bill Act (H.R. 1)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Defense, Dept of (DOD); SENATE; Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 1 (119th)

Medical/Disease Research/Clinical Labs MED

Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Open access policy for peer reviewed research journals Women's health and research Issues impacting blood supply shortages/safety Issues impacting delivery of bone marrow, peripheral blood, and cord blood Clinical trials regulations and coverage Issues impacting laboratory testing and pediatric reference intervals (PRIs) Issues impacting laboratory developed tests (LDTs) Issues impacting drug shortages FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: SENATE; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; President of the U.S.; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Office of Management & Budget (OMB); Office of Science & Technology Policy (OSTP); Defense, Dept of (DOD); White House Office

Medicare/Medicaid MMM

Coverage of blood transfusions under Medicare Hospice Benefit Medicare physician reimbursement issues Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telemedicine/telehealth Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Impact of proposed Medicaid funding cuts on hematology One Big Beautiful Bill Act (H.R. 1) Sickle Cell Disease Comprehensive Care Act (S. 721) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: S. 721 (119th), H.R. 1 (119th), H.R. 879 (119th), S. 1936 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.